Bio-Rad Laboratoriesvs.Hologic
BIO vs HOLX · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Hologic is about 1.8× larger than Bio-Rad Laboratories by market cap; Hologic trades at the lower P/E (31.2 vs 43.5); year to date, Bio-Rad Laboratories leads (+26.0% vs +2.0%).
Side by side
| BIO | HOLX | |
|---|---|---|
| Market cap | $9.7B | $17B |
| Price | $390.34 | — |
| Today | +2.2% | — |
| Return YTD | +26.0% | +2.0% |
| Return 1Y | +25.7% | −3.5% |
| P/E | 43.5 | 31.2 |
| P/S | 3.7 | 4.1 |
| P/B | 1.3 | 3.2 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Bio-Rad LaboratoriesBIO
Clinical diagnostics laboratories buy one part of the range, blood typing among the uses; life science researchers buy the other, for work such as droplet digital PCR.
Full BIO profile →HologicHOLX
Women's health defines the range here, from molecular diagnostic tests to mammography systems and surgical products.
Full HOLX profile →More BIO & HOLX comparisons
Other head-to-heads in the Diagnostics segment.
See where BIO and HOLX sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →